別品名 |
SB203580
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
377.43
|
CAS RN® |
152121-47-6
|
化合物の概要 |
p38 MAPK inhibitor.
|
構造 |
C21H16FN3OS
|
溶媒 |
DMSO43 mg/mL (113.92 mM)WaterInsolubleEthanolInsoluble
|
使用目的 |
SB-203580 is an inhibitor of p38 MAPK that exhibits immunostimulatory, anticancer, and anti-fibrotic activities. In peripheral blood mononuclear cells, SB-203580 increases secretion of IFN-γ. In lung epithelial cells, SB-203580 inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT). Additionally, SB-203580 inhibits proliferation in glioma cells and decreases angiotensin II- and TGF-β1-induced expression of GTGF and fibronectin in other cellular models.
|
参考文献 |
Kuhnol C, Herbarth M, Foll J, et al. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother. 2013 Dec;62(12):1797-809. PMID: 24129764.Chen HH, Zhou XL, Shi YL, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013 Feb;44(2):93-8. PMID: 23376055.Morales MG, Vazquez Y, Acuna MJ, et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. PMID: 22964022.
|
|
メーカー |
品番 |
包装 |
LKT
|
S0500
|
5 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
-20℃
|
|